Lilly wins the backing of EU regulators for its Alzheimer’s disease drug Kisunla in a specific group of patients https://t.co/x2fzm7e9j2 ...

Seoul-based Illimis Therapeutics has raised 58 billion won ($42 million) to fund its research into treatments for Alzheimer’s disease and expand into immune diseases.https://t.co/1bBd93vmef https://t.co/Dtw8pt4XG9 ...

Seoul-based Illimis Therapeutics has raised 58 billion won ($42 million) to fund its research into treatments for Alzheimer’s disease and expand into immune diseases.https://t.co/QiTtfEYSjy https://t.co/XdRh7oCqF8 ...

The average age when people in the Richardson family who carry a gene mutation start to show symptoms of Alzheimer’s disease is 39. Three young siblings in the family hope to change that. https://t.co/4AKaFgvboQ ...

The average age when people in the Richardson family who carry a gene mutation start to show symptoms of Alzheimer’s disease is 39. Three young siblings in the family hope to change that. https://t.co/EG83x9t9Fb ...

The average age when people in the Richardson family who carry a gene mutation start to show symptoms of Alzheimer’s disease is 39.Three young siblings in the family hope to change that. 🔗 https://t.co/l919k115HF https://t.co/3xnvaD5oST ...